益佰制药(600594) - 2024 Q2 - 季度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to the parent company for the first half of 2024 to be between -125 million yuan and -105 million yuan, indicating a loss compared to the same period last year [14]. - In the same period last year, the net profit attributable to the parent company was 127.91 million yuan, with a net profit of 104.07 million yuan after deducting non-recurring gains and losses [7]. - The company’s total profit for the first half of 2023 was 153.64 million yuan [17]. - The company reported earnings per share of 0.162 yuan in the previous period [10]. - The performance forecast period is from January 1, 2024, to June 30, 2024 [15]. Reasons for Expected Loss - The main reason for the expected loss is the cessation of production and sales of the main product, Aidi Injection, leading to a significant decline in revenue and profit [11]. - The decline in revenue is also attributed to price reductions for products such as L-Oplatin Injection, Ginkgo Biloba Injection, and Compound Scolopendra Capsule [18]. Forecast and Risk Disclosure - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant [16]. - The company emphasizes that the forecast data is subject to change and the final financial data will be disclosed in the official half-year report [9]. - The company warns investors to be aware of investment risks due to the anticipated losses [9].